Desvenlafaxine Succinate Patent Expiration

1. Pristiq patent expiration

PRISTIQ's oppositions filed in EPO
PRISTIQ IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6673838 PF PRISM CV Succinate salt of O-desmethyl-venlafaxine
Mar, 2022

(2 years ago)

US8269040 PF PRISM CV Derivatives of venlafaxine and methods of preparing and using the same
Jul, 2027

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6673838 PF PRISM CV Succinate salt of O-desmethyl-venlafaxine
Feb, 2022

(2 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 01, 2013
New Indication(I-675) Feb 14, 2016
M(M-222) Feb 06, 2021

NCE-1 date: 01 March, 2012

Market Authorisation Date: 20 August, 2014

Treatment: For the approved uses and conditions of use, including depression; Maintenance treatment of major depressive disorder (mdd)

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of PRISTIQ before it's drug patent expiration?
More Information on Dosage

PRISTIQ family patents

Family Patents